PAK2 and hepatocellular carcinoma: Another study suggested that METTL3 may also be associated with lenvatinib resistance in HCC cells, driving cancer cell resistance through the METTL3-M6a/EGFR-pak2-erk5 axis; thus, METTL3 may be a potential therapeutic target for drug resistance (35).